Previous close | 1.5000 |
Open | 1.5000 |
Bid | 0.0000 |
Ask | 2.4000 |
Strike | 20.00 |
Expiry date | 2024-08-16 |
Day's range | 1.5000 - 1.5000 |
Contract range | N/A |
Volume | |
Open interest | 1 |
BOSTON, May 21, 2024--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, will present late-breaking data during the 2024 Digestive Disease Week® (DDW) meeting from its pivotal Phase III clinical trial, STARS, which evaluated the efficacy and safety of once-weekly subcutaneous apraglutide in adult patients with short bowel syndrome with intestinal failure (SBS-IF). These findings build on the positive topline data that Ironwood previously announced in February 2024. B
It's been a sad week for Ironwood Pharmaceuticals, Inc. ( NASDAQ:IRWD ), who've watched their investment drop 14% to...
Revenue Falls Short of Expectations While Clinical Trials Show Promising Outcomes